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The  viral  2A  sequence  is  suitable  for  gene  manipulation  in the  Siberian  hamster.
It allows  long-term  simultaneous  over-expression  of 2  genes  in  vitro and  in  vivo.
We  demonstrate  dual  expression  in vitro  in  the  neuroblastoma  cell  line  SH-SY5Y.
We  demonstrate  dual  expression  in  the  hypothalami  of  Siberian  hamsters  and mice.
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Introduction:  The  viral  2A sequence  has  become  an  attractive  alternative  to the traditional  internal
ribosomal  entry  site  (IRES)  for simultaneous  over-expression  of  two  genes  and  in combination  with
recombinant  adeno-associated  viruses  (rAAV)  has  been  used  to  manipulate  gene  expression  in  vitro.
New method:  To  develop  a rAAV  construct  in  combination  with  the viral  2A  sequence  to  allow  long-term
over-expression  of the  vgf  gene  and  ﬂuorescent  marker  gene  for tracking  of  the  transfected  neurones
in  vivo.
Results:  Transient  transfection  of  the AAV  plasmid  containing  the  vgf  gene,  viral  2A sequence  and  eGFP  into
SH-SY5Y  cells  resulted  in eGFP  ﬂuorescence  comparable  to a commercially  available  reporter  construct.
This  increase  in  ﬂuorescent  cells  was  accompanied  by  an  increase  in  VGF  mRNA  expression.  Infusion
of  the  rAAV  vector  containing  the  vgf gene,  viral  2A sequence  and eGFP  resulted  in  eGFP  ﬂuorescence
in the  hypothalamus  of  both  mice  and  Siberian  hamsters,  32 weeks  post  infusion.  In  situ hybridisation
conﬁrmed  that  the location  of VGF  mRNA  expression  in  the  hypothalamus  corresponded  to the  eGFP
pattern  of  ﬂuorescence.
Comparison  with  old method:  The  viral  2A sequence  is much  smaller  than the traditional  IRES  and  therefore
allowed  over-expression  of  the  vgf  gene  with  ﬂuorescent  tracking  without  compromising  viral  capacity.
Conclusion:  The  use of  the viral  2A sequence  in  the  AAV  plasmid  allowed  the  simultaneous  expression
of  both genes  in  vitro.  When  used  in  combination  with rAAV  it resulted  in  long-term  over-expression  of
both  genes  at equivalent  locations  in the  hypothalamus  of  both  Siberian  hamsters  and  mice,  without  any
adverse  effects.
©  2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  licenseAbbreviations: All standard in this ﬁeld∗ Corresponding author. Tel.: +44 0115 951 6604; fax: +44 0115 951 2212.
E-mail address: preeti.jethwa@nottingham.ac.uk (P.H. Jethwa).
ttp://dx.doi.org/10.1016/j.jneumeth.2015.08.013
165-0270/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The use of transgenic and knockout mice has contributed greatly
to our understanding of gene function and disease. However, these
mice models are not only complex to create, but may  not be viable,
or may  produce a complex phenotype reﬂecting developmental
or functional compensation. Gene transfer technologies utilising
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
PCR primers used for the synthesis of VGF-2A fragment, to determine endogenous
VGFmRNA and cyclophilin control.
Gene Forward primer (5′–3′) Reverse primer (5′–3′)
Modiﬁed PCR primers
(for ampliﬁcation of
VGF cDNA)
CCC GGG AAG CTT ACC
ATG AAA ACC TTC ACG
TTG CCG GCA TCC
GGG CCC
TGG GCC AGG ATT CTC
CTC GAC GTC ACC GCA
TGT TAG CAG ACT TCC
TCT GCC CTC TCC ACT
GCC GAG CAC GTG CTG
CTG CAC CGC CCG
VGF mRNA GAC CCT CCT CTC CAC
CTC TC
ACC GGC TCT TTA TGC
TCA GA
Cyclophilin A TCC TGC TTT CAA GAA
TTA TTC C
ATT CGA GTT GTC ACA
GTC AGC
The modiﬁed PCR primers for the ampliﬁcation of VGF cDNA (Accession no.:
NM 001039385.1) from the pSC-B-AMP/KAN blunt cloning vector to produce the
VGF-2A fragment. The forward primer contains a Kozak sequence (in bold) for
initiation of translation, while the reverse primer contains the viral 2A sequence
(underlined) and a point mutation to allow the removal of the stop codon from the
VGF cDNA. Both primers contained unique restriction sites to aid the sub-cloning
process. The VGF mRNA and cyclophilin primers were designed from database
sequences. Sequence data was input into Primer3 in FASTA format and primers
F
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iruses provide a means to overcome some of these limitations. The
ost widely used viral vectors for neuronal over-expression are
ecombinant adeno-associated viruses (rAAV), as they have been
hown to efﬁciently and stably transduce a variety of tissues in
mmunocompetent animals, including mice, rats and Siberian ham-
ters (Daya and Berns, 2008; Jethwa et al., 2010). However these
iruses are limited in their capacity to incorporate foreign DNA by
irtue of their genomic size (approximately 5 kb) (Kay et al., 2001).
lthough hybrids with other viruses have been generated to try to
vercome this limitation (Costantini et al., 1999; Nakai et al., 2000;
ecchia et al., 1999), the low insert capacity remains an issue if
o-expression of genes is required from a single viral vector. For
xample, the combination of a gene of interest and a reporter gene,
uch as green ﬂuorescent protein (GFP), is particularly useful in
rder to enable visualisation of transduced cells both in vitro and
n vivo.
Co-expression of genes can greatly enhance the efﬁciency
nd usefulness of transgenic applications. A number of options
re available to simultaneously express two genes in particular
ells/neurones. Currently the most common approach relies on
ector strategies in which genes are linked by an internal ribo-
omal entry site (IRES) to allow simultaneous expression of genes,
ince the IRES sequence permits the production of multiple pro-
eins from a single mRNA transcript. Ribosomes bind to the IRES in
 5′-cap independent manner and initiate translation (Jang et al.,
988). However, there are two main limitations to the use of the
RES. First, the size of the IRES is often in excess of 500 base pairs,
hich further limits the capacity to incorporate foreign DNA. Sec-
nd, the expression of the downstream gene within the vector is
ften reduced and therefore expression of the two  genes is not
quivalent. Recently it has been shown (Chan et al., 2011) that viral
A sequences can overcome these limitations; with the viral 2A
equence shown to increase reporter gene expression in compari-
on to the IRES sequence. Thus the viral 2A peptide sequence offers
n alternative to the IRES.
The viral 2A sequence was ﬁrst identiﬁed in the picornaviruses
Ryan et al., 1991; Trichas et al., 2008). Viral 2A sequences
re relatively short (approximately 20 amino acids) and contain
he consensus motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro (Ibrahimi
t al., 2009). The sequence acts co-translationally, the formation of
 normal peptide bond between the glycine and proline residues
s prevented, which results in ribosomal skipping (Donnelly et al.,
001) and therefore cleavage of the nascent polypeptide. This
ffect produces multiple genes at equimolar levels. The efﬁciency
f the viral 2A sequence has been demonstrated in a wide range
f eukaryotic cells from yeast to mammals (de Felipe and Ryan,
004), including its effectiveness following insertion between two
eporter genes in vitro (Ryan and Drew, 1994). Importantly, the
iral 2A sequence, in combination with AAV, was  able to func-
ion in the rat brain without any cytotoxic effects (Furler et al.,
2001).
Despite these advantages, the use of viral 2A sequence technol-
gy for in vivo research has been limited. In this study, we utilised
he viral 2A sequence (a) to overcome AAV capacity problems
aced utilising large genes and (b) to over-express VGF and eGFP
n the hypothalamus of Siberian hamsters and mice to determine
ts feasibility in standard and non-standard laboratory animals. We
learly demonstrate that the combination of AAV with the viral 2A
ggc ag t gg a gag  gg c ag a gg a ag t ctg ct a ac a tg 
Gly Se r Gl y Glu Gl y Ar g Gl y Se r Le u Leu Th r C
VGF 2A
ig. 1. The viral 2A sequence. The viral 2A sequence, containing the consensus motif Asp
ascent  polypeptide, resulting in expression of both the VGF gene and eGFP reporter genwere designed using the default criteria (Primer size; 18–27 bp, Melting temperature
55–62 ◦C, Amplicon size 50–150 bp) and obtained from Sigma, Dorset, UK.
sequence results in long term over-expression of VGF mRNA and
the eGFP reporter gene in the hypothalamus of both species.
2. Materials and methods
2.1. Synthesis of construct and viral particles
Construction of the pAAV-CBA-AgRP-IRES-eGFP-WPRE plasmid
(from an original plasmid AAV vector, a kind gift from Dr Miguel
Sena Esteves, University of Massachusetts, Worcester, USA) has
been described previously (Jethwa et al., 2010). We replaced the
AgRP-IRES in this plasmid with VGF cDNA and the viral 2A sequence
from Trichas et al. (2008) (Fig. 1). Full length mouse VGF cDNA
(Accession no.: NM 001039385.1) was  isolated and inserted into
the blunt cloning vector, pSC-B-AMP/KAN (Agilent Technologies,
UK) for ampliﬁcation using modiﬁed PCR primers. The forward
primer contained a Kozak sequence for initiation of translation,
while the reverse primer contained the viral 2A sequence and a
point mutation to allow the removal of the stop codon from the
VGF cDNA (Table 1).
The resulting PCR fragment, which contained the VGF  cDNA
and viral 2A sequence (VGF-2A), was digested with HindIII and
NotI, while the AgRP-IRES sequence was excised from the pAAV-
CBA-AgRP-IRES-eGFP-WPRE plasmid vector using HindIII and AgeI,
the latter producing an identical 5′ overhang (5′-GGCC-3′) to NotI.
The digested plasmid was treated with calf intestinal alkaline
phosphatase (Promega, USA) to prevent re-ligation of the plasmid
without insert. Sure 2 Supercompetent cells (Agilent Technologies,
USA) were used for transformation to prevent DNA rearrange-
ment/deletion, as they lack the Escherichia coli genes implicated in
such events, thereby improving cloning efﬁciency. The VGF-2A PCR
fragment produced by PCR was  cloned in to the original AgRP plas-
mid  to produce the pAAV-CBA-VGF-2A-eGFP-WPRE plasmid vector
(referred to as pAAV-VGF-GFP) (Fig. 2).
c gg t ga c gt c gag  ga g aa t cc t gg c cca
ys Gl y Asp   Val  Gl u Gl u As n Pro  Gl y Pro   
GFP
-Val-Glu-X-Asn-Pro-Gly-Pro, which mediates the co-translational cleavage of the
e in equimolar amounts. Adapted from Trichas et al. (2008).
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Fig. 2. A schematic to show steps leading to the production of rAAV-VGF.  Full length mouse cDNA was isolated and inserted into the blunt cloning vector pSC-B-AMP/KAN for
ampliﬁcation using modiﬁed primers to produce the VGF-2A fragment. This product was  cloned into the pAAV-CBA-AgRP-IRES-GFP backbone (previously used in Jethwa et al.,
2010), following excision of the AgRP-IRES complex to produce pAAV-CBA-VGF-2a-GFP (pAAV-VGF-GFP). This was used for the in vitro checking (Study 1), before then being
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tsed  to produce recombinant AAV-2 (rAAV) by Vector BioLabs (USA) yielding rAAV-
ntermediate early promoter, CBA—chicken -actin promoter, eGFP—enhanced gree
lement.
Following in vitro validation in SH-SY5Y cells, the pAAV-
GF-GFP plasmid was packaged into AAV-2 particles by Vector
ioLabs (PA, USA). The titre obtained was 7.2 × 1012 gc/ml and
ill be referred to as rAAV-VGF. The rAAV-GFP control vector
as purchased from Vector Biolabs (PA, USA); this had a viral
itre of 1 × 1013 gc/ml and expressed eGFP under the control of a
ytomegalovirus (CMV) promoter.
.2. The SH-SY5Y neuroblastoma cell line
The human neuroblastoma SH-SY5Y cells were grown in 25 cm2
issue culture ﬂasks with complete Dulbecco’s modiﬁed Eagle’s
edium/nutrient mixture F-12 Ham, containing 10% foetal bovine
erum, 100 units/l penicillin and 100 mg/l streptomycin (all Sigma-
ldrich, Dorset, UK), which will be referred to as DMEM/F12
omplete. Cultures were maintained at 37 ◦C in a 95% humidiﬁed
ncubator with 5% CO2. Cells were routinely split 1:3 with 0.05%
rypsin (Sigma-Aldrich, Dorset, UK) every 48 h. For differentiation,
he SH-SY5Y cells were seeded at 5 × 104 cells/cm2 in 6-well tis-
ue culture plates (9.5 cm2) in DMEM/F12 complete, and 48 h later
reated with 10 M retinoic acid (RA) (Sigma-Aldrich, Dorset, UK)
or 120 h in accordance with previous studies (Cheung et al., 2009;
ahlman et al., 1984). Cells were visualised by Leica DF420C micro-
cope (Leica Instruments, Milton Keynes, UK).
.3. Study 1: In vitro assessment of viral plasmid pAAV-VGF-GFP
.3.1. Transfection
pAAV-VGF-GFP and pZsGreen1-N1 (a positive control; Clontechaboratories, CA, USA) plasmids were transfected into undiffer-
ntiated SH-SY5Y cells using FuGENE HD (Promega, Wisconsin,
SA) according to the manufacturer’s protocol. Brieﬂy, prior
o transfection, cells at approximately 80% conﬂuence werer in vivo infusion (study 2). ITR—internal tandem repeat, CMV/IE—cytomegalovirus
rescent protein, WPRE—Woodchuck Hepatitis virus post-transcriptional regulatory
transferred to OptiMeM1® reduced serum media containing no
antibiotics (Promega, Wisconsin, USA). Plasmid DNA was  diluted
in OptiMEM1® to give a concentration of 20 g/ml. The FuGENE®
HD transfection reagent was added to achieve a 3:1, reagent: DNA
ratio and 10 l of the reagent:DNA mixture was added to each
well equating to 50 ng of plasmid DNA per well. The cells were
incubated for 72 h prior to assessment of eGFP ﬂuorescence and
VGF mRNA expression. Cells transfected in parallel were further
incubated with RA (10 M)  to induce differentiation prior to eGFP
assessment.
2.3.2. In vitro eGFP expression
eGFP ﬂuorescence in the SH-SY5Y cells was imaged using
the Typhoon Trio+ instrument (excitation maximum = 493 nm;
emission maximum = 505 nm)  and ImageQuant software (GE Life-
Sciences, UK).
2.3.3. In vitro VGF mRNA expression
2.3.3.1. RNA extraction. Prior to harvesting the cells, the DMEM
complete medium was removed, then cells were scraped directly
into 200 l of RNase-free phosphate buffered saline (PBS). Total
RNA was extracted from the cells using the High Pure Isolation kit
according to the manufacturer’s instructions (Roche Life Science,
West Sussex, UK) and as described previously (Brown et al., 2012).
2.3.3.2. cDNA synthesis and ampliﬁcation by PCR. First strand com-
plimentary DNA (cDNA) was  synthesised using the Transcriptor
First Strand cDNA Synthesis kit (Roche Life Science, West Sus-
sex, UK) according to the manufacturer’s protocol. Brieﬂy 2 g of
total RNA was combined with 60 M random hexamer primers
and RNase free water and incubated for 10 min at 65 ◦C before
then being placed on ice. Then 0.5 l transcriptor reverse transcrip-
tase (10 U), 2 l deoxynucleotide mix  (1 mM each), 0.5 l protector
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Nase inhibitor (20 U) and 4 l reaction buffer were added to each
eaction on ice, vortexed and incubated for 10 min  at 25 ◦C for
0 min, followed by incubations at 55 ◦C (30 min), 85 ◦C (5 min) and
hen 4 ◦C to cool. The cDNA was stored at 20 ◦C.
.3.3.3. Quantitative RT-PCR. Quantitative Polymerase Chain Reac-
ions (PCR) were performed with SYBR® green optimised for the
ightCycler 480 (Roche Life Science, UK). All reactions were per-
ormed in triplicate on 384 well plates as per manufacturer’s
nstructions. Brieﬂy each well contained 5 l cDNA in SYBR® Mas-
er Mix  1, 0.25 M primers, and RNase free water in a total volume
f 15 l per well. Samples were pre-incubated at 95 ◦C for 5 min,
ollowed by 40 ampliﬁcation cycles (de-naturation: 95 ◦C for 10 s;
nnealing: 55 ◦C for 10 s and elongation: 72 ◦C for 30 s). The respec-
ive primer sets used can be seen in Table 1.
Ct values were converted to expression levels using a standard
urve produced using a serial dilution of a pooled cDNA made from
ll samples to check linearity and efﬁciency of the PCR reactions.
xpression values were then normalised to cyclophilin A, the most
table reference gene under the experimental conditions.
.4. Study 2: In vivo assessment of the rAAV-VGF viral construct
.4.1. Animals
All animal procedures were approved by the University of Not-
ingham Local Ethical Review Committee and were carried out in
ccordance with the UK Animals (Scientiﬁc Procedures) Act 1986
project licence PPL 40/3604).
Male Siberian hamsters (Phodopus sungorus) aged 4–6 months
n = 12) were taken from a colony maintained by the University of
ottingham (Ebling, 1994). They were housed in individual cages
nder controlled temperature (21 ± 1 ◦C) and on a photocycle of
6 h light/8 h dark (lights off at 11:00 h), with ad libitum access to
ood and water, unless otherwise stated. The diet was  standard lab-
ratory chow comprising of 19% extruded protein and 9% fat (Teklad
019, Harlan, UK).
Male C57BL/6 J mice (Mus  musculus) aged 3 months (n = 12),
ere supplied by Harlan, UK. They were housed in individual
ages under controlled temperature (21 ± 1 ◦C) and on a photo-
ycle of 12 h light/12 h dark (lights off at 19:00), with ad libitum
ccess to food and water. The diet was standard laboratory chow
omprising of 18% extruded protein and 6.2% fat (Teklad 2018,
arlan, UK).
.4.2. Infusion of viral vectors
Animal surgical procedures were carried out as previously
escribed (Jethwa et al., 2010). Brieﬂy, animals were placed in a
opf stereotaxic frame (David Kopf Instruments, NY, USA) under
eneral anaesthesia (0.5–2.5% isoﬂurane), with the incisor bar pos-
tioned level with the interaural line. Using the sutures conﬂuence
regma as a landmark, a small hole was drilled on midline. The
ura mater was pierced just lateral to the mid-sagittal sinus and
 drawn glass capillary microinjector (30-micron tip diameter)
as lowered to the correct location. Using a Nanolitre Injection
ystem (WPI, Stevenage, UK), Siberian hamsters (n = 6/group) or
ice (n = 6/group) were bilaterally infused with 200 nl of the viral
ector (rAAV-GFP or rAAV-VGF-GFP) directed towards the PVN
anteroposterior +0.03, mediolateral ±0.03, dorsoventral −0.58
co-ordinates from Paxinos and Franklin, 2012) over one minute.
ollowing infusion, the glass microinjector was kept in place for an
dditional 5 min  to allow for diffusion and prevention of backﬂow
hrough the cannula track, the incision was closed using Michel
lips. Analgesia was maintained via subcutaneous injection of
arprofen (50 mg/kg Rimadyl, Pﬁzer, Kent, UK) administered before
urgery. The surgically-prepared Siberian hamsters and mice were
llowed a seven day recovery period, during which they werece Methods 256 (2015) 22–29 25
handled on a daily basis, received analgesia and had access to a
palatable diet consisting of soaked Teklab diet. One  week post viral
infusion, Siberian hamsters and mice underwent metabolic analysis
to determine locomotor activity in the Comprehensive Labora-
tory Animal Monitoring System (CLAMS) as previously described
(Jethwa et al., 2010). At 32 weeks post infusion, animals were
euthanised by injection of pentobarbital sodium (Euthatal; Rhone
Merieux, Harlow, UK). Brains were immediately removed and
snap frozen on dry ice for subsequent measurement of GFP  and
VGF expression by ﬂuorescence imaging and in situ hybridisation,
respectively.
2.4.3. In situ hybridisation
Coronal sections (20 m)  of brains were cut, using a cryo-
stat (Microm, USA), and arranged on 3-aminopropyltriethoxysaline
(APES) coated slides. Sections on the slides were ﬁxed in 4%
paraformaldehyde (PFA) before being dried for storage at −70 ◦C.
Riboprobes were generated from the blunt pSC-B-AMP/KAN
plasmid (containing VGF cDNA) and pSLAX13-eGFP (containing
eGFP—a kind gift from Dr Dylan Sweetman, University of Notting-
ham). Antisense transcripts were generated using T7 polymerase
(NEB, USA) in the presence of digoxigenin (DIG)/ﬂuorescein-12-
uridine-5-triphosphate, which could subsequently be detected.
Fluorescence in situ hybridisation was performed as described
previously (Sweetman et al., 2008). Brieﬂy, riboprobes were puri-
ﬁed on a G-50 spin column (Boehringer Mannheim, USA) and a
small aliquot subjected to gel electrophoresis to determine yield
and integrity of the riboprobes. Slides containing the sections
were thawed to room temperature, ﬁxed with freshly prepared
4% PFA/0.1% gluteraldehyde before being treated with proteinase
K (10 g/ml). Slides were incubated with 80 l 1× hybridisation
solution (Sigma, St. Louis, MO,  USA) containing 1 l of riboprobe
for 6 h at 65 ◦C/min at room temperature. A cover slip was placed
on each slide and slides were incubated overnight at 65 ◦C in
a humidiﬁed in situ hybridisation chamber. Post hybridisation,
the section were washed twice with hybridisation solution at
65 ◦C for 10 min, followed by 2 washes with maleic acid buffer
containing 0.1% Tween-20 (MABT, pH 7.5) at room tempera-
ture. The sections were blocked with MABT/2%Roche blocking
agent (Roche, USA) for 1 h at room temperature and incubated
overnight with anti-digoxigenin antibody conjugated to alkaline
phosphatase (1:2000) at 4 ◦C. Slides were subsequently washed 3×
with MABT for 1 h at room temperature following an overnight
incubation at 4 ◦C in MABT. For the colour reaction, sections
were washed with 1-methyl-5-thiotetrazole (NMTT) containing
nitroblue tetrazolium (NBT) and 5-bromo-3-indoxyl-phosphate
(BCIP), which yields a black–purple precipitation. The reaction
was stopped by washing the sections in 5× TBSTw (1×TBS, 0.1%
TweenTM 20, 0.2 mM sodium azide) overnight at 4 ◦C. This pro-
cess was  repeated the following day to intensify the signal and
reduce background. Cover slips were applied to the slides with
a small amount of Vectashield media (Vector Labs, CA, USA) and
sealed with nail polish. Images were captured using a Leica DMRB
microscope (Leica Microsystems, Germany) and Openlab soft-
ware (UK). eGFP was excited using the 488 nm laser (emission
520 nm).
2.5. Statistical analysis
Descriptive statistics (means and standard error mean (SEM))
were generated using GraphPad PRISM version 6.0 (GraphPad Soft-
ware Inc, USA). Transfection studies (Section 2.3) and food intake
data (Section 2.4) were compared using a one-way ANOVA. A two-
way ANOVA (treatment vs. time) was used to analyse the locomotor
activity data from CLAMS (Section 2.4). P < 0.05 was considered
statistically signiﬁcant.
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Fig. 3. eGFP and VGF expression in SH-SY5Y cells following transient transfection with the pAAV-VGF-GFP plasmid. (A) eGFP expression in SH-SY5Y cells 72 h post transfection
w ted with the pAAV-VGF-GFP plasmid following differentiation with 10 M RA for 120 h.
Q  pAAV-VGF-GFP or pZsGreen1-N1 (control) in undifferentiated SH-SY5Y cells. Values are
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Table 2
Comparison of food intake and locomotor activity one week post viral infusion in
the  Siberian hamster and mouse.
Food intake (g) Locomotor activity
(beam breaks)
rAAV-GFP rAAV-VGF rAAV-GFP rAAV-VGF
Siberian
hamster
3.71 ± 0.24 4.01 ± 0.07 23.10 ± 5.10 23.11 ± 7.38
Mouse 3.76 ± 0.32 4.13 ± 0.25 97.93 ± 9.17 100.13 ± 17.16
Mean food intake (g) measured in the home cage and mean 24 h values for the num-ith  the pAAV-VGF-GFP plasmid. (B) eGFP expression in the SH-SY5Y cells transfec
uantiﬁcation of (C) eGFP expression and (D) VGF mRNA 72 h post transfection with
roup  means ± SEM (n = 3), *** p < 0.0001 vs. control.
. Results
.1. Study 1: In vitro assessment of viral plasmid pAAV-VGF-GFP
Prior to viral packaging, the ability of the pAAV-VGF-GFP
lasmid to simultaneously express both VGF and eGFP was
eriﬁed following transient transfection of SH-SY5Y cells. Fluo-
escent microscopy conﬁrmed widespread expression of eGFP in
ndifferentiated SH-SY5Y cells 72 h post transfection (Fig. 3A).
reatment of the transfected SH-SY5Y cells with 10 M RA for 120 h
nduced differentiation, at which point eGFP expression expanded
eyond the cell body and extended to the neurite projections
see Fig. 3B). The increase in eGFP expression in undifferenti-
ted cells was similar to that observed following transfection
f the SH-SY5Y cell line with the positive control construct,
ZsGreen1-N1, expressing ZsGreen1-N1 under the control of a CMV
romoter (GFP expression: pZsGreen1-N1; 442.8 ± 8.8, pAAV-VGF-
FP; 366.0 ± 6.5, p = n.s. Fig. 3C). Furthermore, the increase in eGFP
xpression in undifferentiated cells was associated with an increase
n VGF mRNA expression. Transfection of the SH-SY5Y cells with
AAV-VGF-GFP resulted in a 20-fold increase in VGF mRNA expres-
ion (VGF mRNA: 20.6 ± 0.1, F = 5.830, p < 0.0001, Fig. 3D), compared
o control cells transfected with pZsGreen1-N1.
.2. Study 2: In vivo assessment of viral construct rAAV-VGF
.2.1. Animal behaviour
Approximately 95% of the animals that underwent the viral
icroinjection surgery recovered fully from anaesthesia and were
eintroduced to their home cages. Once reintroduced, all animals
aintained good health throughout the duration of the study and
ormal behaviour was observed, with no changes in initial food
ntake or locomotor activity observed one week post viral infusion
Table 2)..2.2. Hypothalamic expression of eGFP and VGF mRNA
Post mortem analysis of eGFP by ﬂuorescence microscopy
as performed at 32 weeks post infusion of the viral constructsber  of beam breaks in the metabolic cages (Comprehensive Lab Animal Monitoring
System; CLAMS). Values are mean ± SEM.
rAAV-GFP and rAAV-VGF in Siberian hamsters and mice. Expres-
sion of eGFP was widespread in the hypothalamus of both species,
as well as along the infusion tract. eGFP expression was observed
in both rAAV-GFP and rAAV-VGF infused Siberian hamsters and
mice. The spread of the eGFP expression from viral constructs was
similar for both rAAV-GFP and rAAV-VGF vectors, up to 400 m in
the lateral plane (Fig. 4). As seen in previous studies (Jethwa et al.,
2010), there were instances of unilateral expression in several of
the animals, which was  independent of the vector infused (Fig. 4).
Within the hypothalamus, eGFP expression was apparent along
the third ventricle, suprachiasmatic nucleus, lateral hypothala-
mic  area, the anterior hypothalamic nucleus, the paraventricular
nucleus (PVN), arcuate nucleus (ARC), ventromedial hypothalamus
and dorsomedial nucleus in both species receiving either rAAV-
GFP or rAAV-VGF viral vectors (Fig. 4). Confocal analysis revealed
there was  widespread eGFP expression in the cell soma and cell
processes of the PVN of both Siberian hamsters (Fig. 4C and G) and
mice (Fig. 4D and H) receiving either rAAV-GFP or rAAV-VGF viral
vectors.
In situ hybridisation analysis of the brain sections demonstrated
over expression of VGF in the hypothalamus of all animals infused
with rAAV-VGF vector (Fig. 5). This over-expression corresponded
to the pattern of eGFP expression and associated ﬂuorescence
(Fig. 5). In contrast, animals infused with rAAV-GFP only expressed
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Fig. 4. Use of the viral 2A sequence in the rAAV-VGF construct results in widespread eGFP expression in the hypothalamus.  Representative pictures of eGFP expression in the
hypothalamus of Siberian hamsters and mice which received bilateral (200 nl) injections of either rAAV-GFP or rAAV-VGF directed to the PVN. (A–D) eGFP expression
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GF mRNA in low amounts in the ARC (Fig. 5), indicating areas of
ndogenous VGF expression.
. Discussion
The ability to co-express two or more genes in the same cells is
ighly desirable, particularly for identiﬁcation of transfected cells
ollowing viral transfection in vivo. We  have shown that the viral
A sequence allows the simultaneous expression of both GFP and
he gene of interest (VGF) in the brains of a non-standard labo-
atory species, the Siberian hamster, which is comparable to the
ouse.
The role of VGF was ﬁrst highlighted by the phenotype of mice
acking the functional vgf (non-acronymic) gene (Hahm et al.,
999), which suggested an anabolic role for this gene. However we
ave previously shown that VGF mRNA expression in the Siberian
amster is regulated in relation to changes in its body weight cycle,
ith signiﬁcantly higher hypothalamic expression in the winter
atabolic state as compared to the summer anabolic state (Barrett
t al., 2005). Subsequent functional studies using VGF-derived pep-
ides in both mice and Siberian hamsters, have suggested a catabolic
ole (Bartolomucci et al., 2006; Jethwa et al., 2007; Lewis et al.,
015). The lack of antibodies towards this gene for the detection
f speciﬁc derived peptides, as well as our use of a non-standard
nimal model, directed us to develop a novel strategy to over-
xpress VGF in the hypothalamus of adult Siberian hamsters. We
lso wanted to visualise transfected cells using a reporter gene, ashamsters and (B) mice and in the cell soma and processes of the PVN of (C) Siberian
in the hypothalamus of (E) Siberian hamsters and (F) mice and in the cell soma and
previously observed in our studies on the over-expression of AgRP
(Jethwa et al., 2010).
While our previous studies have shown that over-expression
of two genes using IRES is feasible (Jethwa et al., 2010), the size
of the IRES and VGF gene alone would have acceded the capacity
of the rAAV and possible leading to issues with regards to sufﬁ-
cient titre. Thus we  designed a vector utilising the viral 2A sequence
for simultaneous expression of VGF mRNA and eGFP. The viral 2A
sequence has not only been shown to be reliable, but also causes
no cytotoxic effects in transgenic mice (Trichas et al., 2008). The
viral 2A sequence is particularly useful in vector strategies (AAV
and retroviral vectors) where the capacity to incorporate foreign
DNA is limited. Indeed, the viral 2A sequence has been shown to
reduce the size of the viral vector, improving transfection efﬁciency
and viral titre, and thus transduction efﬁcacy, leading to increased
expression of both the gene of interest and reporter (Szymczak and
Vignali, 2005).
We  demonstrate the functionality of our plasmid vector
(pAAV-VGF-GFP), which utilises the viral 2A sequence, in SH-
SY5Y cells. High levels of eGFP expression were observed 72 h
following transient transfection of pAAV-VGF-GFP into undif-
ferentiated cells, which was comparable to the commercially
available plasmid, pZsGreen1-N1. The increase in eGFP expres-
sion was  accompanied by a signiﬁcant increase in VGF mRNA
in pAAV-VGF-GFP transfected cells as compared to cells trans-
fected with pZsGreen1-N1. Furthermore, differentiation of the
cell line to a more neuronal-like phenotype with retinoic acid
28 J.E. Lewis et al. / Journal of Neuroscience Methods 256 (2015) 22–29
Fig. 5. VGF mRNA and eGFP expression patterns are similar following rAAV-VGF infusion into the hypothalamus of both Siberian hamsters and mice. Representative pictures of
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uGFP  expression (left) and VGF mRNA expression via in situ hybridisation (right) in
njections of either rAAV-GFP (A and C) or rAAV-VGF (B and D) directed to the PVN.
esulted in expression of eGFP beyond the cell body into the neurite
rojections.
The AAV vector (rAAV-VGF) was then produced from this plas-
id  vector and infused into the hypothalamus of Siberian hamsters
nd mice to conﬁrm the effectiveness of the viral 2A sequence
n vivo. We  have shown that the over-expression was still present in
oth species at 32 weeks post microinjection, while in situ hybrid-
sation showed that the VGF mRNA expression was  co-localised
ith eGFP expression. Whether this over-expression is equal in
oth species remains to be determined; unfortunately the in situ
ybridisation method using the DIG does not lend itself to quantiﬁ-
ation, as the colour reaction is repeated to increase the intensity of
he signal and reduce the background. This may  account for the dif-
erences between the species, as sections were analysed in batches
ccording to species rather than treatment.
Nonetheless, the function of viral 2A sequence appears not
o show any attenuation in expression levels across generations
Trichas et al., 2008). Post mortem analysis revealed a high number
f cells, over a large area of the brain, expressed the vectors at 32
eeks post infusion. Despite the bilateral infusion of 200 nl and a
icropipette tip of 30 m,  it was apparent that cells 300–400 m
way also expressed the vector. Cells more dorsal in the brain adja-
ent to the tract of the micropipette also expressed the vectors.
igher lateral expression was noted in some of the animals, a reﬂec-
ion of a technical issue with the infusion of viral vectors at low
olumes through small diameters, something we have noted pre-
iously (Jethwa et al., 2010). Furthermore this may  result in areas
f uneven expression potentially giving rise to differences between
pecies and/or animals.Thus, we have shown that the viral 2A sequence can be used
uccessfully to over-express two genes simultaneously in vitro and
n vivo. Indeed, Trichas et al. (2008) stated that the advantage of
sing 2A sequences over the commonly used IRES sequence is theypothalamus of Siberian hamsters (A and B) and mice (C and D) receiving bilateral
 bar = 2.5 mm.
ability to co-express both genes at nearly equal levels. Indeed 10
fold differences in IRES-controlled expression have been noted
(Martin et al., 2006), while the length of the gene preceding (5′) the
IRES has recently been shown to inﬂuence the expression of the fol-
lowing (3′ to the IRES) reporter (Payne et al., 2013), demonstrating
the unreliability of the sequence for simultaneous gene expres-
sion. These effects have not been observed for plasmid and/or
viral vectors which utilise the viral 2A sequence, which is partic-
ularly important when high levels of expression of both genes are
required (Furler et al., 2001). However, as with all systems, there is
a potential limitation to the use of the viral 2A sequence. Since the
viral 2A sequence is added to the C-terminal of the protein encoded
upstream of the sequence, this may  affect function and/or activity of
that protein, although this has not been observed in any of the stud-
ies published to date (Furler et al., 2001; Trichas et al., 2008). Further
studies concerning the function and safety of the viral 2A sequence
are required, but no adverse effects were noted in our studies fol-
lowing infusion of viral 2A sequence containing vectors. Indeed,
the sequence successfully mediated co-translational ‘cleavage’ to
express two  genes within the hypothalamus of Siberian hamsters
akin to that in the mouse and other rodent models (Furler et al.,
2001; Trichas et al., 2008).
Overall, the results further support the use of AAV vectors for
manipulating gene function in vivo, particularly in non-standard
laboratory models. We have shown that the AAV construct using
the viral 2A sequence resulted in simultaneous expression of VGF
and eGFP, both in vitro and in vivo. Furthermore, the AAV construct
results in long-term expression in vivo.Acknowledgements
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